Gemella hemolysans (G. hemolysans) (G. hemolysans)

Gemella hemolysans is a Gram-positive, catalase-negative, facultatively anaerobic coccus that is part of the normal human flora, primarily residing in the oral cavity and upper respiratory tract (Source: StatPearls, NCBI). Although it is generally considered a commensal organism, it can function as an opportunistic pathogen, leading to serious infections such as infective endocarditis, meningitis, and brain abscesses, especially in individuals with underlying health conditions or prosthetic devices (Source: PubMed, Journal of Clinical Microbiology). The bacterium is known for being fastidious and can be difficult to identify using traditional culture methods, often requiring advanced techniques like MALDI-TOF MS or 16S rRNA sequencing for accurate diagnosis (Source: PMC). Treatment typically involves the use of beta-lactam antibiotics, though susceptibility testing is recommended due to potential resistance (Source: MSD Manuals). Because Gemella hemolysans is a whole organism rather than a specific protein or receptor, it is classified as a pathogen rather than a molecular drug target. Its clinical significance has increased with the rising number of immunocompromised patients and the use of more sensitive diagnostic tools. In cases of endocarditis, it often presents subacutely but can lead to significant valvular destruction if not treated promptly. The organism's ability to form biofilms on prosthetic surfaces further complicates therapeutic interventions.

Other names

Neisseria hemolysans

Inhibition of bacterial cell wall synthesis (beta-lactams, glycopeptides) or inhibition of protein synthesis (aminoglycosides, lincosamides).